HC Wainwright Has Positive Forecast for DTIL FY2030 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Analysts at HC Wainwright lifted their FY2030 earnings per share estimates for Precision BioSciences in a report issued on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $1.24 per share for the year, up from their previous forecast of $1.09. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.69) per share.

Several other equities research analysts have also recently commented on DTIL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday, August 5th. JonesTrading restated a “buy” rating and issued a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Oppenheimer began coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Precision BioSciences has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Precision BioSciences Stock Performance

Precision BioSciences stock opened at $7.42 on Thursday. The company has a current ratio of 12.82, a quick ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $9.62. The company has a market cap of $204.79 million, a PE ratio of -2.65 and a beta of 1.27. The company’s 50-day moving average is $7.42 and its two-hundred day moving average is $6.42.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%.

Hedge Funds Weigh In On Precision BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DTIL. HBK Sorce Advisory LLC acquired a new position in shares of Precision BioSciences during the 4th quarter worth about $38,000. Engineers Gate Manager LP bought a new position in Precision BioSciences during the 4th quarter worth approximately $43,000. Occudo Quantitative Strategies LP bought a new position in Precision BioSciences during the 4th quarter worth approximately $52,000. Miller Financial Services LLC grew its holdings in Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after purchasing an additional 5,000 shares during the period. Finally, Virtu Financial LLC acquired a new position in Precision BioSciences during the third quarter valued at approximately $84,000. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.